Teva Pharmaceuticals to acquire Emalex Biosciences in US$700M deal to strengthen the neurology pipeline

USA—Teva Pharmaceuticals has announced plans to acquire neuroscience-focused company Emalex in a transaction valued at US$700 million upfront, with an additional US$200 million payable upon achievement of regulatory and commercial milestones.

The deal reflects Teva’s continued expansion of its neuroscience portfolio and aligns with the company’s “pivot to growth” strategy, as described by executive vice president of business development Evan Lippman.

According to Lippman, the acquisition strengthens Teva’s position in central nervous system disorders and reinforces its focus on late-stage, differentiated assets that address areas of high unmet medical need.

Integration of Emalex’s neurology pipeline

Through the acquisition, Teva will absorb Emalex’s neurology pipeline, with a particular emphasis on its lead candidate ecopipam.

The asset represents a first-in-class therapeutic candidate developed for the treatment of paediatric Tourette’s syndrome and has already achieved positive results in Phase III clinical trials.

Emalex plans to submit a regulatory application for ecopipam in the United States in the second half of 2026.

If approved, the therapy could potentially reach the market as early as the following year.

This would mark a significant milestone for Tourette’s treatment, as it would become the first new therapeutic option in the indication in more than a decade.

A differentiated mechanism in Tourette’s treatment

Unlike currently available therapies, including Otsuka and Lundbeck’s Abilify (aripiprazole), which act on dopamine 2 (D2) receptors, ecopipam targets dopamine 1 (D1) receptors.

Teva executives believe this distinct mechanism could offer improvements in efficacy, tolerability, and safety for patients.

Lippman noted that this pharmacological differentiation could make ecopipam a more attractive option for both clinicians and patients.

He emphasized that the therapy sits within Teva’s core neuroscience interest and benefits from orphan drug designation, highlighting its relevance in a field marked by significant unmet clinical need.

Addressing unmet needs in paediatric patients

Teva also highlighted the limited long-term treatment adherence among paediatric patients with Tourette’s syndrome.

According to Lippman, only about 30% of patients receiving pharmacological therapy remain on treatment over time, largely due to tolerability and effectiveness limitations associated with existing options.

The introduction of a novel mechanism-based therapy, such as ecopipam, could therefore improve treatment persistence and clinical outcomes in this patient population.

Commercial outlook and market expectations

In a research note, analysts at Jefferies projected that ecopipam could significantly enhance Teva’s financial performance if successfully approved and commercialised.

They estimated that the therapy could achieve up to US$1 billion in peak annual sales in the United States, assuming a 2035 loss of exclusivity timeline.

The analysts further suggested that ecopipam would likely be positioned in a refractory treatment setting, following the use of antipsychotics, where Teva may have stronger pricing flexibility.

Teva’s broader growth strategy

Teva’s acquisition of Emalex comes at a time when the company is experiencing strong momentum in its innovative medicines division, which recorded 41% year-on-year growth in the first quarter of 2026.

This performance has provided Teva with greater flexibility to pursue selective acquisitions aligned with its strategic priorities.

Lippman stated that the company does not face immediate pressure from a patent cliff, allowing it to pursue transactions in a more deliberate and targeted manner.

He added that Teva focuses primarily on late-stage, de-risked assets within neurology and inflammation, including therapies for rare and underserved indications.

While Teva currently prioritises this disciplined acquisition strategy, Lippman indicated that the company may also consider earlier-stage opportunities in the future as its pipeline strategy evolves.